The cancer drug, best known as a game-changer for chronic myeloid leukemia, lowers insulin resistance through a similar mechanism as TZDs without the negative effects.
The cancer drug imatinib—marketed as Gleevec and known as a game-changer for conditions like chronic myeloid leukemia—may prove the same in type 2 diabetes (T2D), according to a study published recently in Diabetes.
Researchers in the United States and in South Korea found that imatinib controls PPARy, which lowers the level insulin resistance and thus reduces the risk of hyperglycemia and obesity. PPARy affects how the body metabolizes glucoses and stores fat, and also affects immune and inflammatory responses.
This same mechanism of action was at work with the class of drugs known as the thiazolidinediones or TZDs, the most famous of which was rosiglitazone, or Avandia. Risks reported in the New England Journal of Medicine forced Avandia off the market and others in the class followed, although a followed up trial exonerated the drug.
The study team noted that the phosphorylation of PPARy is related to developing diabetes; taking away the phosphoric acid from PPARy has an anti-diabetic effect. In the laboratory, the team found that imatinib had the same “blocking” effect on PPARy phosphorylation but without some of the effects seen in the TZDs.
Researchers can see the “what” but don’t understand the “why” just yet. “Although studies have shown that (imatinib) treatment may show improved insulin sensitivity and decreased blood glucose in patients with known diabetes, the exact cause hasn’t been proven yet,” said Jang Hyun Choi, PhD, assistant professor. Ulsan National Institute of Science and Technology (UNIST), in South Korea.
The team tested imatinib in mice that had been fed a high-fat diet. The drug improved insulin sensitivity without causing severe side effects that had been observed with the TZDs.
Reference
Choi SS, Kim ES, Jung JE, et al. PPARy antagonist Gleevec improves insulin sensitivity and promotes the browning of white adipose tissue Diabetes. 2016; 65(4):829 doi: 10.2337/db15-1382.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More